Central Trust Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Central Trust Company’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$331	Hold	1	–	–	﹤0.01%	1526
2025 Q4	$553	Hold	1	–	–	﹤0.01%	1432
2025 Q3	$456	Buy	+1	New	+$407	﹤0.01%	1371
2024 Q1	–	Sell	-67	Closed	-$12.8K	–	1376
2023 Q4	$12.8K	Hold	67	–	–	﹤0.01%	1041
2023 Q3	$11.9K	Hold	67	–	–	﹤0.01%	1024
2023 Q2	$12.7K	Hold	67	–	–	﹤0.01%	998
2023 Q1	$13.4K	Hold	67	–	–	﹤0.01%	1004
2022 Q4	$15.9K	Hold	67	–	–	﹤0.01%	948
2022 Q3	$13K	Hold	67	–	–	﹤0.01%	992
2022 Q2	$10K	Hold	67	–	–	﹤0.01%	1035
2022 Q1	$11K	Hold	67	–	–	﹤0.01%	1065
2021 Q4	$11K	Hold	67	–	–	﹤0.01%	1039
2021 Q3	$13K	Hold	67	–	–	﹤0.01%	989
2021 Q2	$11K	Hold	67	–	–	﹤0.01%	996
2021 Q1	$9K	Hold	67	–	–	﹤0.01%	927
2020 Q4	$9K	Hold	67	–	–	﹤0.01%	900
2020 Q3	$10K	Hold	67	–	–	﹤0.01%	856
2020 Q2	$10K	Hold	67	–	–	﹤0.01%	831
2020 Q1	$7K	Sell	67 -67	-50%	-$7.73K	﹤0.01%	909
2019 Q4	$15K	Hold	134	–	–	﹤0.01%	873
2019 Q3	$11K	Hold	134	–	–	﹤0.01%	885
2019 Q2	$10K	Hold	134	–	–	﹤0.01%	909
2019 Q1	$13K	Hold	134	–	–	﹤0.01%	834
2018 Q4	$10K	Sell	134 -1,000	-88%	-$76.9K	﹤0.01%	887
2018 Q3	$99K	Hold	1,134	–	–	0.01%	570
2018 Q2	$112K	Hold	1,134	–	–	0.01%	538
2018 Q1	$135K	Hold	1,134	–	–	0.01%	520
2017 Q4	$144K	Buy	1,134 +1,000	+746%	+$126K	0.01%	527
2017 Q3	$16K	Hold	134	–	–	﹤0.01%	875
2017 Q2	$11K	Hold	134	–	–	﹤0.01%	934
2017 Q1	$7K	Hold	134	–	–	﹤0.01%	1001
2016 Q4	$5K	Hold	134	–	–	﹤0.01%	1070
2016 Q3	$9K	Hold	134	–	–	﹤0.01%	957
2016 Q2	$7K	Hold	134	–	–	﹤0.01%	1006
2016 Q1	$8K	Hold	134	–	–	﹤0.01%	976
2015 Q4	$13K	Hold	134	–	–	﹤0.01%	929
2015 Q3	$11K	Hold	134	–	–	﹤0.01%	955
2015 Q2	$16K	Hold	134	–	–	﹤0.01%	901
2015 Q1	$14K	Hold	134	–	–	﹤0.01%	922
2014 Q4	$13K	Hold	134	–	–	﹤0.01%	923
2014 Q3	$10K	Hold	134	–	–	﹤0.01%	978
2014 Q2	$8K	Hold	134	–	–	﹤0.01%	994
2014 Q1	$9K	Hold	134	–	–	﹤0.01%	968
2013 Q4	$9K	Hold	134	–	–	﹤0.01%	952
2013 Q3	$9K	Buy	+134	New	+$6.68K	﹤0.01%	962

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Central Trust Company's ALNY Position: Q1 2026 in Review

Central Trust Company held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 1 share worth $331. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Central Trust Company first reported a position in ALNY in Q3 2013 and has held it in 45 quarters since. The position peaked at $144K in Q4 2017. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Central Trust Company held 1 share of Alnylam Pharmaceuticals worth $331 as of Q1 2026.
Central Trust Company left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Central Trust Company's portfolio in Q1 2026, its #1526 holding.
Central Trust Company first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 45 quarters since.
Central Trust Company's Alnylam Pharmaceuticals position peaked at $144K in Q4 2017.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.